Riva Spar 18mg Patch 30’s

Riva Spar 18mg Patch contains Rivastigmine, an acetylcholinesterase inhibitor effective for treating moderate Alzheimer’s disease and dementia associated with Parkinson’s disease. This transdermal patch offers a steady release of medication over 24 hours, improving patient compliance and making it easier to manage cognitive symptoms compared to oral medications. The patch is designed for comfort and convenience, ensuring that patients receive the necessary dose consistently.

Uses:

• Treatment of moderate Alzheimer’s disease
• Management of dementia related to Parkinson’s disease

Side Effects:

• Common side effects may include nausea, vomiting, diarrhea, and application site irritation.
• Serious side effects can include severe allergic reactions and changes in heart rhythm. Seek medical attention for any unusual symptoms.

Key Features:

• Contains 18mg of Rivastigmine for effective symptom management
• Convenient once-daily application through a transdermal patch
• Provides a continuous release of medication for improved adherence

FAQ:

1. What is Riva Spar Patch used for?
   • Riva Spar Patch is utilized to treat moderate Alzheimer’s disease and dementia related to Parkinson’s disease.
2. How is the Riva Spar Patch applied?
   • The patch should be applied to clean, dry, and hairless skin, typically on the upper arm or chest, and should be changed daily.
3. What should I do if I forget to apply the Riva Spar Patch?
   • Apply the patch as soon as you remember. If it is close to the time for your next patch, skip the missed application and resume your regular schedule. Do not use two patches simultaneously.
4. Are there any serious side effects I should be aware of?
   • While most side effects are mild, serious reactions can occur. Contact your healthcare provider if you experience severe allergic reactions or significant changes in heart rhythm.

References:

• European Medicines Agency. (2020). “Rivastigmine transdermal patch.” [Accessed on 5th May 2023]. Available from: EMA
• National Institutes of Health. (2021). “Rivastigmine transdermal system.” [Accessed on 5th May 2023]. Available from: MedlinePlus